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Abstract
Background: HMG CoA reductase inhibitors (statins) in patients with bacteremic sepsis have shown significant survival 
benefits in several studies. There is no data on the effect of statins in candidemic patients, however in-vitro models 
suggest that statins interfere with ergesterol formation in the wall of yeasts.
Methods: This retrospective matched- cohort study from 1/2003 to 12/2006 evaluated the effects of statins on 
patients with candidemia within intensive care units. Statin-users had candidemia as a cause of their systemic 
inflammatory response and were on statins throughout their antifungal therapy, while non-statin users were matched 
based on age +/- 5 years and co-morbid factors. Primary analysis was 30-day survival or discharge using bivariable 
comparisons. Multivariable comparisons were completed using conditional logistic regression. All variables with a p-
value less than 0.10 in the bivariable comparisons were considered for inclusion in the conditional logistic model.
Results: There were 15 statin-users and 30 non-statin users that met inclusion criteria, all with similar demographics 
and co-morbid conditions except the statin group had more coronary artery disease (P < 0.01) and peripheral vascular 
disease (P = 0.03) and lower median APCAHE II scores (14.6 vs 17, p = 0.03). There were no differences in duration of 
candidemia, antifungal therapy or Candida species between the groups. Statins were associated with lower mortality 
on bivariable (OR 0.09, 95% CI 0.11-0.75, p = 0.03) and multivariable (OR 0.22, 95% CI 0.02-2.4, p = 0.21) analyses 
compared to controls; although, in the latter the protective effect lacked statistical signficance.
Conclusion: In our small, single-center matched-cohort study, statins may provide a survival benefit in candidemia, 
however further studies are warranted to validate and further explore this association.
Background
Candidemia is the fourth common cause of nosocomial
blood stream infections and is associated with a signifi-
cant mortality [1,2]. Delays in antifungal therapy have
been associated with increased hospital costs of over
$6,000 per patient and overall mortality [3,4]. The role of
3-hydroxy-3methylglutaryl-coenzyme A (HMG CoA)
reductase inhibitors (statins) in improving outcomes bac-
teremic sepsis is currently being debated with recent
papers showing significantly improved survival in
patients with systemic inflammatory response syndrome
(SIRS) in the intensive care unit (ICU), in patients with
chronic kidney renal disease and patients with commu-
nity acquired pneumonia and influenza [5-9]. One expla-
nation of this effect is that statins in animal models have
shown to reduce inflammatory markers, in particular the
release of cytokines and cytotoxic effects of neutrophils
[10,11]. The reduction in inflammatory cytokines has
also been demonstrated in patients in a prospective ran-
domized study comparing simvastatin to placebo where
there was a significant reduction in tumor necrosis factor
alpha (TNF-α) and interleukin-6 (IL-6) in the statin
group [12].
Yeasts use the same HMG CoA reductase as humans,
however their end-product is ergosterol rather than cho-
lesterol [13,14]. In-vitro studies have demonstrated that
simvastatin greatly inhibits the growth of Candida spe-
cies [15,16]. We performed a review to determine if there
was a clinical benefit of statin therapy throughout anti-
fungal therapy in intensive care unit patients with con-
firmed candidemia.
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Methods
Setting
This study was performed at the University of Maryland
Medical Center, a tertiary care hospital with over 200
intensive care unit (ICU) beds, and the study was
approved by the University of Maryland Institutional
Review Board.
Definitions
We completed a retrospective matched-cohort study per-
formed between 1/2003 and 12/2006. Statin-users
included were at least 45 years old, taking a statin (sim-
vastatin, atorvastatin, or pravastatin) present in any med-
ical or surgical ICU at the onset of candidemia. The
exposed patients or statin-users had to remain on a statin
from the onset of their candidemia to the end of appro-
priate antifungal therapy and have a SIRS response (based
on Society of Critical Care Medicine definitions [17]). For
every statin-user, there were 2 matched unexposed, non-
statin users based on age within 5 years of each case, co-
morbid conditions and antifungal therapy who developed
candidemia within an ICU while present in any ICU.
Only the initial episode of candidemia per patient was
evaluated for both groups and statin-users and non-statin
users were excluded if there was positive blood cultures
for any other organism within 24 hours either side of the
sentinel blood culture for yeast. Statin users and non-
users were also excluded if another active cause for the
SIRS response was found (e.g hospital acquired pneumo-
nia, urosepsis, Clostridum difficile colitis, or catheter-
related bacteremia), or if they died either prior to the
diagnosis of candidemia or before receiving any antifun-
gal therapy.
Data collection
The data collected from both groups included patient
demographics, co-morbid conditions, the age adjusted
Charlson Comorbidity Index (CCI) [18], APACHE II
score at the time of onset of the index candidemia blood
draw, the type and dose of statin used, Candida species,
initial empiric antifungal therapy, and 30-day survival or
discharge. The primary aim was to determine whether
statin-users had improved survival over a similarly
matched-cohort of non-statin users.
Statistical analysis
Bivariable comparisons were completed using t-tests for
normally distributed continuous variables, Wilcoxon
rank sum for non-normally distributed continuous vari-
ables and the Fisher-exact test for categorical variables.
Bivariable statistical comparisons presented in Table 1
were completed without considering the matching.
Matched bivariable comparisons and multivariable com-
parisons were completed using conditional logistic
regression. All variables in the bivariable comparisons
were considered for inclusion in the conditional logistic
model. Each individual parameter was then analyzed in
the conditional model by itself to determine significant
association with mortality under a matched analysis and
then was added into the multivariable model and left in
the model if it confounded the primary association
between statin exposure and mortality with a 10% or
greater change in the point estimate. The statin exposure
was forced into the models, as it was the primary expo-
sure of interest. All analyses were completed using SAS
version 9.1 (Cary, NC).
Results
Out of a total of 418 individual episodes of candidemia
during the four-year study period, there were 24 (5.7%)
patients on statin therapy. After exclusion criteria were
included, there were 15 statin users and 30 non-statin
users who met the full inclusion criteria. (Figure 1) The
main demographic and comorbid differences (Table 1)
was as expected coronary artery disease (P < 0.01). Other
statistically significant differences between the exposure
groups included APACHE II score (14.9 vs 18.2, p = 0.03),
initial white cell count (12.2 vs 16.8, p = 0.02), and 30 day
survival (73% vs 37%, p = 0.02), which were all higher in
the statin-user group. There were no significant differ-
ences between the two groups with Candida  species
obtained from blood cultures or duration or selected
empiric antifungal therapy given to each group. (Table 2)
The main statins observed to be used were atorvastatin
(9/15, 60%), simvastatin (5/15, 33%) and pravastatin (1/
15, 7%). In the matched conditional logistic bivariable
analysis (table 3), statin exposure the only individual risk-
factor associated with a statistically significant effect on
mortality (p = 0.03, OR 0.09, 95%CI 0.11 - 0.746), while
both higher APACHE II score and higher white blood cell
count trended toward increased mortality (p = 0.08). In
the multivariable conditional logistic regression analysis
that included APACHE II score and statin therapy, statin
exposure was associated with a statistically non-signifi-
cant reduced mortality (OR 0.22, 95% CI 0.02-2.4, p =
0.21) compared to unexposed patients.
Discussion
This is the first study to evaluate the effects of statins on
sepsis caused by candidemia in isolation from other
causes. This study finds that there may be a clinical bene-
fit of statin therapy in ICU patients with candidemia and
an associated SIRS response. Within this small cohort,
our data suggest statins given concurrently with antifun-
gal therapy for candidemia were associated with a 91%
reduction in mortality in the bivariable analysis and an
attenuated 78% reduction in odds of mortality when con-
trolling for severity of illness with APACHE II score.
However the odds ratio (OR) can overestimate the rela-Forrest et al. BMC Infectious Diseases 2010, 10:152
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Table 1: Demographics, co-morbid conditions and antifungal therapy of study groups.
Variable Patients on Statins N (% or +/- SD) Patients Not on Statins N (% or SD) p-value†
Age (years) 65.9 (+/- 9.4) 67.7 (+/- 8.7) 0.52
Male 11 (73%) 12 (40%) 0.06
Medical ICU 9 (60%) 24 (80%) 1
Median Charlson Score (IQR) 8 (5-8) 6 (5-7) 0.15
Apache II 14.9 (+/- 3.8) 18.2 (+/- 5.0) 0.03*
AST 20 [17,140] 34 [24,86] 0.34
ALT 22 [19,135] 44 [24,113] 0.17
Albumin 2 (+/- 0.3) 2 (+/- 0.5) 0.76
Bicarbonate 23.9 (+/- 5.6) 22.9 (+/- 5.5) 0.57
Creatinine 2.8 (+/- 2.3) 2.7 (+/- 1.7) 0.80
CPK 129 [39,1502] 45 [35,163] 0.45
Hematocrit 29.8 (+/- 4.2) 29.2 (+/- 4.9) 0.66
PT 14.2 (+/- 2.4) 14.0 (+/- 2.9) 0.79
PTT 31.6 (+/- 8.6) 39.3 (+/- 16.9) 0.06
WBC 12.2 (+/- 4.5) 16.8 (+/- 8.8) 0.02*
Platelets 241 (+/- 127) 221 (+/- 130) 0.62
Heart disease 15 (100%) 16 (53%) <0.01*
Heart failure 7 (47%) 6 (20%) 0.08
Obstructive lung disease 4 (27%) 8 (27%) 1.0
Renal insufficiency 7 (47%) 7 (23%) 0.08
Dialysis 4 (27%) 9 (30%) 1.0
Stroke 6 (40%) 7 (23%) 0.3
Cancer 2 (13%) 4 (13%) 1.0Forrest et al. BMC Infectious Diseases 2010, 10:152
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tive risk (RR). In this case the RR = 0.42 for mortality in
Table 1 (27%/63%) is much less protective than the OR
would suggest. Candidemia is a marker of severe illness in
the ICU and diagnosis is often delayed because of low
blood culture yields [3,19]. With the overall candidemia
related mortality over 30% in this setting, any extra bene-
fit for drugs that modulate the immune system may be
useful.
This finding is supported by in-vitro models suggesting
that statins may interfere with ergesterol production in
Diabetes 10 (67%) 17 (57%) 0.75
HIV/AIDS 0 0
Hypertension 12 (80%) 20 (67%) 0.49
Peripheral vascular disease 5 (33%) 2 (7%) 0.03*
Transplantation 1 (7%) 1 (3%) 1.0
Median duration of 
Candidemia (days)
2 (+/-0.6) 1 (+/-0.9) 0.2
Survival 11 (73%) 11 (37%) 0.02*
* Significant values, p < 0.05
APACHE II: Acute Physiology and Chronic Health Evaluation II, AST: aspartate transaminase, ALT: alanine transaminase, CPK: creatine 
phosphokinase, ICU: Intensive Care Unit, IQR; Interquartile range, PT: Prothrombin time, PTT: partial thromboplastin time, WBC; white blood 
cell count.
†All continue variables presented as mean, standard deviation (SD) except ALT, AST, and CPK, which were non-normally distributed and 
presented as median with interquartile range.
Table 1: Demographics, co-morbid conditions and antifungal therapy of study groups. (Continued)
Table 2: Candida species and initial empiric antifungal medication received by exposure status
Patients on Statins, N (%) Patients Not on Statins, N (%) p-value
Candida Sp.
Candida albicans 6 (40%) 11 (37%) 0.3
Candida glabrata 4 (27%) 11 (37%) 0.5
Candida parapsilosis 3 (20%) 4 (13%) 0.57
Candida tropicalis 1 (7%) 4 (13%) 0.5
Mixed Candida* 2 (13%) 0 0.2
Antifungal Therapy
Amphotericin B 1 (7%) 1 (3%) 1.0
echinocandin 7 (47%) 12 (40%) 0.75
fluconazole 7 (47%) 17 (57%) 0.54
* Mixed isolates were 1 C. albicans and C. glabrata, and 1 C. albicans and C. parapsilosis.Forrest et al. BMC Infectious Diseases 2010, 10:152
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yeast [20]. The effect of statins on ergesterol production
and cytokines may also explain why the statin group had
a reduced inflammatory response compared to the con-
trols in our study [10,15]. Macreadie et al. have demon-
strated in-vitro that by supplementing Candida albicans
with ergesterol in aerobic culture can overcome the inhi-
bition caused by statins [13]. Importantly, Nash et al have
demonstrated that the addition of pravastatin or lovasta-
tin does not affect fluconazole activity [21].
There are now several larger retrospective studies
showing the benefits of statins in bacterial sepsis. Initially,
Liappis et al demonstrated that patients on statins had
greater than 7 times greater chance of survival with sepsis
[22]. Two recent prospective observational studies using
large cohorts have also demonstrated similar findings.
Almog et al showed in an ICU that only 2.4% of patients
on a statin developed bacterial sepsis compared with 19%
(p < 0.001) who were not on a statin [9]. Gupta et al also
found that hemodialysis patients taking statins were also
significantly less likely to be hospitalized for severe sepsis
[5]. There have been several other retrospective and
observational studies with similar findings with bactere-
mia [23-25].
The timing of initiation of statins with regards to the
onset of sepsis is still being determined. This is because it
takes several days for statin to achieve desirable concen-
trations [26]. Pre-admission use of a statin has shown rel-
ative risk reductions in large cohort studies evaluating
community acquired pneumonia and ICU admission
[27,28]. Thomsen et al showed that the use of preadmis-
sion statin up to 180 days prior to admission demon-
strated a 25-30% mortality rate reduction at 90 days [27].
Also, Christensen et al showed about a 20% mortality rate
reduction between statin users and non-users [28]. How-
e v e r  M a j u m d a r  e t  a l  s h o w e d  i n  a  p r o s p e c t i v e  c o h o r t
study for pneumonia that the benefit of statins disap-
peared after adjustment for confounders [6]. These con-
founders which Thomsen et al discuss include the
"healthy-user" effects of patients being on statins with
patients being better educated and socioeconomically
better off than non-users [27]. We were unable to control
for these "healthy-user" factors, but in an ICU setting
may be less relevant. Based on our exclusion criteria to
identify only SIRS induced by candidemia, every effort
was made to find matching controls. Major differences
were that statin-users were more likely to have heart fail-
ure, renal insufficiency, stroke, and peripheral vascular
disease. Since our hypothesis was that statins would be
protective and statins had higher comorbidity, we expect
this to bias our findings to the null. Thus, if we were able
to obtain perfect matching, we would have seen statins as
being more protective.
The differences in APACHE II scores between the sta-
tin-users and unexposed groups, despite the statin-users
Table 3: Risk-factors for mortality*
Model Exposure Odds Ratio (95% CI) p-value
1 Statin Exposure 0.09 (0.11-0.746) 0.03
2 Apache II 1.5 (0.95-2.4) 0.08
3 Male 1.8 (0.4-8.0) 0.46
4 WBC count 1.2 (0.98-1.4) 0.08
5 PTT 1.02 (0.96-1.085) 0.52
6 Renal insufficiency 0.30 (0.05, 1.7) 0.17
7 Statin 0.22 (0.02, 2.4) 0.21
Apache II 1.4 (0.8, 2.3) 0.27
PTT = partial thromboplastin time; WBC = white blood cell
*For heart disease and heart failure in the single exposure models and white blood cell count in the multivariable model there were 
insufficient numbers in the strata to calculate a meaningful confidence interval.Forrest et al. BMC Infectious Diseases 2010, 10:152
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having a higher Charlson comorbidity score could be
either due to statin effect or how patients were matched.
A prospective study by Novack et al randomly assigned
ICU patients to receive a statin or not and evaluated their
cytokine responses [12]. They found that statins signifi-
cantly reduced TNF-α and IL-6 despite the statin goup
having a higher APACHE II score [12]. Similarly, Schmidt
e t  a l  s h o w e d  t h a t  s t a t i n - u s e r s  i n  t h e  I C U  w i t h  m u l t i -
Figure 1 Distribution of candidemic patients by statin and non-statin-user. Footnote: ICU = Intensive care unit
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organ dysfunction may have better survival with reduc-
tion in inflammatory markers [29].
We recognize our study limitations being the small
sample size, with associated limited power, and patients
were from a single center. In addition, we were not able to
standardize the statins used given the retrospective
nature of the study. There was exceptional difficulty in
obtaining enough patients with candidemia without
another cause of their SIRS and remaining on a statin
throughout their antifungal therapy and then matching
the cases and controls as closely as possible to our defini-
tions. We suspect that most patients have their statins
discontinued because of the lack of an intravenous for-
mulation despite being able to deliver the drug down
feeding tubes, although recent data suggest that this
method may lead to elevated plasma levels of the statins
[30].Our limitations presented are similar to other studies
published on statins and bacteremic sepsis [27,28,31].
Conclusions
This retrospective matched-cohort study suggests that
there may be a survival benefit to remaining on a statin
with a SIRS response from candidemia, but an overall sta-
tistically significant survival benefit was not observed
when adjusted by APACHE II score. Further studies are
warranted to define the optimal dose of statin and timing
of therapy in a prospective manner. Additionally, larger
studies are warranted to validate and further explore this
association.
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